

Autocertificazione assenza di conflitto di interessi

Il sottoscritto Prof. Francesco Lo Coco, nato a Palermo il 31/10/1955, residente in via Catone n. 34, 10192 Roma, Cod. Fisc. MLCCFNC55R30G273P, in qualità di *Resp. scientifico ed ECM* del programma *FAD BLOOD ONLINE 2018-19* (www.bloodonline.it);

ai sensi dell'art. 3.3 sul Conflitto di Interessi, pag. 18,19 dell'Accordo Stato-Regione del 19 aprile 2012, per conto del Provider Infomedica (n. 3 - accreditamento standard)


DICHIARA

che negli ultimi due anni ha avuto i seguenti rapporti anche di finanziamento con soggetti portatori di interessi commerciali in campo sanitario: *Speaker's bureau*: Teva, Novartis, Lundbeck; consulenze: Teva, Orsenix

che negli ultimi due anni non ha avuto rapporti anche di finanziamento con soggetti portatori di interessi commerciali in campo sanitario.

Roma, 10 maggio 2018

In fede,



Prof. Francesco Lo Coco

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name **FRANCESCO LO COCO**
 Address **DEPT. OF UNIVERSITY TOR VERGATA, ROME , ITALY**
 Telephone **+39.06.20903220**
 Fax **+39.06.20903221**
 E-mail **Francesco.lo.coco@uniroma2.it**

Nationality **Italy**
 Date of birth **30.10.1955**

WORK EXPERIENCE

• Dates (from – to)

1987-2002	Head, Molecular Biology Laboratory, Hematology Section, Dept. of Human Biopathology of the University "La Sapienza", Rome
1993 -2002	Senior staff member, Hematology Section, Dept. of Cellular Biotechnologies and Hematology University "La Sapienza", Rome
2002-2005	Associate Professor of Hematology, Head of Integrated Diagnostic of Oncohematologic diseases, University Tor Vergata, Rome
2005-present	Full Professor of Hematology, University Tor Vergata of Rome

EDUCATION AND TRAINING

• Dates (from – to)	1974-1981	Medical Doctor, University of Pisa
	1982-1985	Board Certificate in Hematology, University "La Sapienza" of Rome
	1992-1994	Visiting Scientist, Dept. of Pathology, Columbia University, New York

**PERSONAL SKILLS
AND COMPETENCES**

*Acquired in the course of life and career
but not necessarily covered by formal
certificates and diplomas.*

MOTHER TONGUE Italian

OTHER LANGUAGES

Spanish, excellent in verbal, reading and writing skills
English, excellent in verbal, reading and writing skills

**TECHNICAL SKILLS
AND COMPETENCES**

*With computers, specific kinds of
equipment, machinery, etc.*

Computer excellent ability to work with office package

ADDITIONAL INFORMATION

ANNEXES

Selected Papers

- 1) Lo Coco F, Diverio D, Pandolfi PP, et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. **Lancet** 340: 1437,1992.
- 2) Lo Coco F, Pelicci PG, D 'Adamo F et al. Polyclonal hematopoietic reconstitution in leukemia patients at remission after suppression of specific gene rearrangement. **Blood** 82l: 606,1993.
- 3) Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc-finger encoding gene,BCL-6 in diffuse large-cell lymphoma. **Science** 262: 747,1993.
- 4) Lo Coco F, Ye BH, Lista F, et al. Rearrangements of the BCL-6 gene in diffuse largecell non-Hodgkin's lymphoma **Blood** 83: 1757, 7994.
- 5) Offit K, Lo Coco F, Louie DC, Parsa NZ, Leung D, Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A , Ladany M, Jhanwar S , Dalla-Favera R , Chaganti R SK. Rearrangement of the BCL-6 gene as a prognostic marker in diffuse large-cell lymphoma. **New England Journal of Medicine** 331:74, 1994.
- 6) Mandelli F, Diverio D, Awisati G, Luciano A , Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M , Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G , Vegna ML, Visani G, Muus P, Willemze R, Jehn U, Pelicci PG, Biondi A, Lo Coco F. Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. **Blood** 90:1014,1 997.
- 7) Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F. Early detection of relapse by prospective RT-PCR analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. **Blood** 92:784, 1998
- 8) Di Croce L, Raker VA, Corcaro M, Fazi F, Fanelli M, Fuks F , Lo Coco F, et al. Methyltransferase recruitment to target promoters as a mechanism of DNA hypermethylation by an oncogenic transcription factor. **Science** 295: 1079,2002.
- 9) Lo Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E, Pogliani EM, Di Bona E, Micalizzi C, Kropp M, Venditti A, Tafuri A, Mandelli F, Gentuzumab ozogamicin ("mylotarg") as a single agent for molecularly relapsed acute promyelocytic leukemia. **Blood** 104:199, 2004.
- 10) Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigema B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo Coco F, Pelicci PG, Martelli MF. Cytoplasmic Nucleophosmin (NPM) Identifies a Subtype of Acute Myelogenous Leukemia With A Normal Karyotype and NPM Gene Mutations. **New England Journal of Medicine** 352:2 54,2005.
- 11) Hasan SK, Mays AN, Ottone T, Ledda A, La Nasa G, Cattaneo C, Borlenghi E, Melillo L, Montefusco E, Cervera J, Stephen C, Satchi G, Lennard A, Libura M, Byl JA, Osheroff N, Amadori S, Felix CA, Voso MT, Sperr WR, Esteve J, Sanz MA,Grimwade D, Lo-Coco F. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. **Blood** 2008 Oct 15;112(8):3383-90.

- 12) Lo-Coco F, Avvisati G, Paoloni F et al. for the Italian GIMEMA Cooperative Group. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. **Blood** 116:3171, 2010.
- 13) Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P, Ottone T, Consalvo MI, Lavorgna S, Bulian P, Ammatuna E, Angelini DF, Diamantini A, Campagna S, Ottaviani L, Sarlo C, Gattei V, Del Poeta G, Arcese W, Amadori S, Lo-Coco F, Venditti A. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. **Blood** 116:2295, 2010
- 14) Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, et al. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. **Blood** 115:453, 2010
- 15) Lo-Coco F, Avvisati G, Vignetti M et al. Arsenic trioxide and retinoic acid for acute promyelocytic leukemia. **New England Journal of Medicine** 368: 111-121, 2013.
- 16) Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, Specchia G, Breccia M, Levis A, Sica S, Finizio O, Kropp MG, Fioritoni G, Cerqui E, Vignetti M, Amadori S, Schlenk RF, Platzbecker U, Lo-Coco F. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. **J Clin Oncol.** 2014;32(30):3406-12.
- 17) Angelini DF, Ottone T, Guerrera G, Lavorgna S, Cittadini M, Buccisano F, Bardi M, Gargano F, Maurillo L, Divona M, Noguera NI, Consalvo MI, Borsellino G, Bernardi G, Amadori S, Venditti A, Battistini L, Lo-Coco F. A leukemia-associated CD34/CD123/CD25/CD99 immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. **Clinical Cancer Research**;21(17):3977-85, 2015.
- 18) Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco E. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and U, **New England Journal of Medicine** 374(12):1197-8, 2016.

20) Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S, Alfonso V, Paoloni F, Piciocchi A, Avisati G, Ferrara F, Di Bona E, Albano F, Breccia M, Cerqui E, Sborgia M, Kropp MG, Santoro A, Levis A, Sica S, Amadori S, Voso MT, Mandelli F, Lo-Coco E. PML-RARA kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukemia treated with ATRA and ATO or ATRA and chemotherapy. *Leukemia* 2016 May 20. doi: 10.1038/leu.2016.122.

Roma, 15.02.2018

Autorizzo il trattamento dei dati personali ai sensi della Legge 196/03

francesca Lo Coco